Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 6Active not recruiting 4Completed 2Terminated 1Suspended 1Not yet recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Head & Neck 1Dermatologic 1

Conditions

Eyelid Squamous Cell Carcinoma 1

Interventions

Specimen Handling 29Magnetic Resonance Spectroscopy 20Biopsy 19Cyclophosphamide 8venetoclax 5Bevacizumab 5Vincristine 4Taxes 4Surgical Procedures, Operative 4Radiotherapy, Intensity-Modulated 4Nivolumab 4Etoposide 4Cetuximab 4Azacitidine 4fludarabine phosphate 3fludarabine 3decitabine and cedazuridine drug combination 3X-Rays 3Radiosurgery 3Radiation 3Prednisone 3Doxorubicin 3zanubrutinib 2trastuzumab deruxtecan 2prednylidene 2olaparib 2iadademstat 2deltacortene 2Tacrolimus 2Standard of Care 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Suspended × Radiotherapy, Image-Guided × 90 days × Clear all
NCT06568172 2026-05-13

Testing the Addition of an Immunotherapy Drug, Cemiplimab (REGN2810), Plus Surgery to the Usual Surgery Alone for Treating Advanced Skin Cancer

National Cancer Institute (NCI)

Phase 3 Suspended
420 enrolled
DermatologicHead & NeckSarcoma

Eyelid Squamous Cell Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡